๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

โœ Scribed by Bhuvaneswari Ramaswamy; Steven P Povoski; Chris Rhoades; Joan Allen; Marsha Hauger; Donn Young; William Burak; William Farrar; Lisa Yee; Kari Kendra; Sivagurunathan Somasundaram; Robert Z Orlowski; Charles L. Shapiro

Publisher
Springer US
Year
2005
Tongue
English
Weight
227 KB
Volume
93
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of adjuvant chemotherapy w
Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer
โœ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w

Phase II trial of neoadjuvant docetaxel
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer
โœ Jacqueline Vuky; Christopher Porter; Christina Isacson; Matthew Vaughan; Paul Ko ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND: Prostate cancer trials investigating neoadjuvant hormonal therapy, followed by surgery, have demonstrated that elimination of all tumor cells from the primary site is rare. The authors report a phase 2 trial assessing the efficacy and toxicity of docetaxel and gefitinib